Tamoxifen
FDA Approved
Description
Tamoxifen is a selective estrogen receptor modulator primarily used in breast cancer treatment. It has been used off-label in cases of virginal breast hypertrophy to reduce breast tissue growth by blocking estrogen receptors. The medication can help manage severe cases of juvenile macromastia when conservative measures fail.
Indications & Therapeutic Use
Breast cancer, virginal breast hypertrophy, gynecomastia, mastalgia
Linked Diseases:
virginal breast hypertrophy
C536821
Global Availability (8 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Tamoxifen
| Generic Name | Tamoxifen |
| Brands | 1 brand available |
| Active Ingredient | Tamoxifen citrate |
| Drug Class | Breast cancer |
| Manufacturer | AstraZeneca |
| Dosage Forms | Oral tablets 10mg, 20mg |
| Medical Code | L02BA01 |
| Orphan Status | No |
| Cold Chain | Not Required |
| Lead Time | 3 days |
| Reg. Status | FDA Approved |
| Countries | 8 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations9 Validated Nodes